CASI Pharmaceuticals, Inc., a biopharmaceutical company with operations in China, the United States, and globally, focuses on developing and selling pharmaceutical products and therapeutics for various ailments. The company's flagship product, EVOMELA, is an intravenous formulation of melphalan used as a pre-transplant conditioning treatment and to provide palliative care for patients suffering from multiple myeloma. In addition, CASI Pharmaceuticals operates an impressive pipeline of hematology/oncology assets that include CNCT 19, a CAR-T investigative product; BI-1206, an antibody with a singular mode-of-action; CB-5339, a VCP/p97 inhibitor aimed at treating malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. CASI Pharmaceuticals holds licensing agreements with Juventas Cell Therapy, BioInvent International, Black Belt Therapeutics, and Cleave Therapeutics, and distribution agreements with China Resources Pharmaceutical Commercial, Pharmathen Global, and Riemser Pharma. Established in 1991, the company's headquarters are in Beijing, China.